Navigation Links
Ovid Supports Chinese Medical Research Market with the Release of OvidChinese, a Local-Language Portal Solution to Search Chinese-Language Medical Resources
Date:9/1/2011

NEW YORK, Sept. 1, 2011 /PRNewswire/ -- Ovid, part of Wolters Kluwer Health and a global leader in the development and delivery of customizable research information solutions for the medical, scientific and academic markets, is pleased to announce the release of Ovid's latest local language search portal, OvidChinese. OvidChinese allows healthcare practitioners, clinicians, students, and researchers to search, browse, and manage results of core Chinese-language medical content.

"We are excited to introduce OvidChinese at the Beijing Book Fair," said Karen Abramson, President & CEO of Wolters Kluwer Health Medical Research. "OvidChinese fills an important gap in this high-growth market for Chinese medical publishers who want to broaden the reach of their content through our global network and for researchers, students and healthcare practitioners who want a reliable, efficient way to search important Chinese medical literature to improve patient care, support medical studies, and inform ongoing research."

OvidChinese is accessible anytime, anywhere a user has internet access.  Users can search and browse content by subject area, and perform other research tasks including:

  • Enter search terms in Simplified Chinese
  • Refine book searches by specific criteria
  • Search multiple resources simultaneously
  • Access premium resources published by the top publishers in China
  • Navigate between table of contents, chapters, and sections
  • Email or export images from the image gallery to PowerPoint
  • Capture key content by exporting citations to PDF
  • Offer Chinese-language information to students, faculty, and clinicians

From August 31 through September 04, Ovid will offer demonstrations of OvidChinese at the Beijing International Book Fair in China, Stand E2.C30.

Ovid continues to expand its content offerings on OvidChinese with new and established partnerships among leading Chinese medical publishers, including Higher Education Press (HEP), People's Medical Publishing House (PMPH), People's Military Medical Digital Press (PMMDP), and Shanghai Scientific & Technical Publishers (SSTP).

More than 400 titles are currently available on the portal with several hundred more titles planned for later this year. The content covers Traditional Chinese medicine, acupuncture, and therapeutic areas such as surgery and regenerative medicine, among other disciplines. Learn about all the current title offerings at www.ovid.com/ovidchinese. Some of the core medical titles available on OvidChinese include:

  • Massotherapy as the Best Medicine, PMMDP
  • Diagnosis, Treatment and Care of Respiratory Diseases by TCM, PMMDP
  • Case Records of Clinical Practice in Internal Medicine, PMMDP
  • Research on the Functional Genomics of the Rat Regenerating Liver, HEP
  • Regenerative Medicine: From Basic to Clinical Research, SSTP

Ovid is already well-established within the research community known around the world for OvidSP, the industry-leading online research platform with unique tools and features designed to maximize search precision and efficiency, and simplify and speed analysis and workflow—all in a simple, integrated and easy-to-use system. Ovid introduced its first local-language portal in 2010 with OvidFrancais and has portals planned for Arabic, Spanish, among other languages.  

About Ovid and Wolters Kluwer Health

Ovid® is a global information solutions provider offering clinicians, professionals, students, and researchers in the medical, scientific, and academic fields customizable solutions of content, tools, and services that make research smarter, faster, and more effective. Ovid is used by the world's leading colleges and universities; medical schools; academic research libraries and library consortia; hospitals and healthcare systems; pharmaceutical, engineering and biotechnology companies; and HMOs and clinical practices.

Ovid is part of Wolters Kluwer Health, a leading global provider of information, business intelligence and point-of-care solutions for the healthcare industry. Wolters Kluwer Health is part of Wolters Kluwer, a market-leading global information services company with 2010 annual revenues of euro 3.6 billion ($4.7 billion).


'/>"/>
SOURCE Wolters Kluwer Health
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. New Study Supports Efficacy of Vagus Nerve Stimulation for Treatment-Resistant Depression
2. Cell Therapeutics, Inc. (CTI) Supports Panel Discussion on Women and Lung Cancer on Capitol Hill
3. Survival Data in FDA Approval for ERBITUX(R) (Cetuximab) Supports use as a Single Agent in Patients with Advanced Colorectal Cancer
4. Cost-Effectiveness Study Supports Use of EUFLEXXA(TM) by Rheumatologists for Pain Relief in Patients with Knee Osteoarthritis
5. New Data from the Framingham Heart Study Supports PAT Technology to Diagnose Early Cardiovascular Disease
6. Powerful New Efficacy Data in Moderate and Severe Hypertensive Patients Supports FDA Approval of AVALIDE(R) (Irbesartan-Hydrochlorothiazide) as the First Combination Therapy for Initial Use in Patients Likely to Need Multiple Drugs to Achieve Their Blood
7. Interim Safety Analysis Supports Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-cell Lymphoma
8. Interim Analysis Supports Continuation of Cell Genesys VITAL-1 Phase 3 Clinical Trial of GVAX Immunotherapy for Prostate Cancer
9. FDA Advisory Committee Supports Efficacy and Safety of Zyprexa(R) Long-Acting Injection (LAI) for Schizophrenia Treatment
10. HUYA Bioscience Intl Announces Clinical Trial Milestones in China for Promising New Anti-Arrhythmic Compound; Data Supports Desirable Safety Profile
11. New Clinical Data Further Supports Chromium Picolinates Role in Enhancing Brain Activity in Older Adults
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... , Jan. 18, 2017  Dermata Therapeutics, ... products to treat a variety of dermatological diseases, ... compound DMT210, in a Phase 2 acne rosacea ... to downregulate the proinflammatory cytokines in the skin ... acne rosacea. This clinical trial, ...
(Date:1/18/2017)... 18, 2017 The report " Automated Breast Ultrasound System ... Scanner), By End User (Hospitals, Diagnostic Imaging Centers), Industry Analysis Report, Regional Outlook ... Argentina , Germany , UK, France ... Russia , China , Japan , ... , Saudi Arabia , UAE, South Africa ...
(Date:1/18/2017)... , Jan. 18, 2017  Tarix Orphan LLC today ... granted a Rare Pediatric Disease (RPD) designation for the ... Dystrophic Epidermolysis Bullosa (RDEB), a rare genetic skin disorder. ... treatment is limited to supportive care. "The ... Drug Designation previously granted by the FDA in this ...
Breaking Medicine Technology:
(Date:1/18/2017)... ... 18, 2017 , ... Catalent Pharma Solutions, the leading global ... health products, today announced that Mr. Michael Merges, Director of Strategic Growth, Catalent ... held at the Mayflower Hotel, Washington DC, on Jan. 24 – 26, 2017. ...
(Date:1/18/2017)... ... January 18, 2017 , ... Floundering on New Year’s ... and the perfect time for a reset. The U.S. Apple Association agrees and recommends ... many of the factors that contribute to heart disease. , The U.S. Apple Association ...
(Date:1/17/2017)... ... January 17, 2017 , ... For breast cancer clinicians and ... or those who desire a more intimate review and analysis of its highlights, a ... to Bedside—is being offered by Imedex on February 4, 2017 in Chicago. Chaired by ...
(Date:1/17/2017)... ... January 17, 2017 , ... Etymotic ... National Association of Music Merchants (NAMM) winter trade show, Booth #2876, at the ... ER•4® has long been the gold standard for high-definition, in-ear earphones. This classic ...
(Date:1/17/2017)... ... January 17, 2017 , ... Peoples Health is ... Health network on Dec. 1, 2016. Peoples Health, a Metairie-based Medicare Advantage company, ... an exciting addition to our provider network, and the addition will benefit our ...
Breaking Medicine News(10 mins):